A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase
A Phase I, Multi-center, Open Label Dose Escalation Study of LDK378, Administered Orally in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
Sponsor: Novartis Pharmaceuticals
Listed as NCT01283516, this PHASE1 trial focuses on Tumors Characterized by Genetic Abnormalities of ALK and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 8 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Apr 2019 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Jan 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands , Aurora, United States , Barcelona, Spain , Boston, United States , Cologne, Germany , Essen, Germany , Glasgow, United Kingdom , Heidelberg, Germany , Leicester, United Kingdom , Leuven, Belgium and 11 more locations